302 related articles for article (PubMed ID: 11960598)
21. MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
Han J; Chen Q
Int J Clin Exp Pathol; 2015; 8(10):12698-707. PubMed ID: 26722459
[TBL] [Abstract][Full Text] [Related]
22. Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways.
Wang H; Cai S; Ernstberger A; Bailey BJ; Wang MZ; Cai W; Goebel WS; Czader MB; Crean C; Suvannasankha A; Shokolenkoc I; Wilson GL; Baluyut AR; Mayo LD; Pollok KE
Clin Cancer Res; 2013 May; 19(10):2699-709. PubMed ID: 23536437
[TBL] [Abstract][Full Text] [Related]
23. The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Caporali S; Alvino E; Starace G; Ciomei M; Brasca MG; Levati L; Garbin A; Castiglia D; Covaciu C; Bonmassar E; D'Atri S
Pharmacol Res; 2010 May; 61(5):437-48. PubMed ID: 20026273
[TBL] [Abstract][Full Text] [Related]
24. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
25. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.
Wedge SR; Porteus JK; May BL; Newlands ES
Br J Cancer; 1996 Feb; 73(4):482-90. PubMed ID: 8595163
[TBL] [Abstract][Full Text] [Related]
26. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
27. Dual repair modulation reverses Temozolomide resistance in vitro.
Barvaux VA; Ranson M; Brown R; McElhinney RS; McMurry TB; Margison GP
Mol Cancer Ther; 2004 Feb; 3(2):123-7. PubMed ID: 14985452
[TBL] [Abstract][Full Text] [Related]
28. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.
Hirose Y; Berger MS; Pieper RO
Cancer Res; 2001 Mar; 61(5):1957-63. PubMed ID: 11280752
[TBL] [Abstract][Full Text] [Related]
29. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
Alvino E; Castiglia D; Caporali S; Pepponi R; Caporaso P; Lacal PM; Marra G; Fischer F; Zambruno G; Bonmassar E; Jiricny J; D'Atri S
Int J Oncol; 2006 Oct; 29(4):785-97. PubMed ID: 16964376
[TBL] [Abstract][Full Text] [Related]
30. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.
Zhang J; Hummersone M; Matthews CS; Stevens MF; Bradshaw TD
Oncology; 2015; 88(1):28-48. PubMed ID: 25277441
[TBL] [Abstract][Full Text] [Related]
31. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT
PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319
[TBL] [Abstract][Full Text] [Related]
32. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
[TBL] [Abstract][Full Text] [Related]
33. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
[TBL] [Abstract][Full Text] [Related]
34. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
Bobola MS; Silber JR; Ellenbogen RG; Geyer JR; Blank A; Goff RD
Clin Cancer Res; 2005 Apr; 11(7):2747-55. PubMed ID: 15814657
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of ILK promotes temozolomide resistance in glioma cells.
Liang F; Wang B; Bao L; Zhao YS; Zhang SM; Zhang SQ
Mol Med Rep; 2017 Mar; 15(3):1297-1304. PubMed ID: 28138714
[TBL] [Abstract][Full Text] [Related]
36. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Wedge SR; Porteous JK; Newlands ES
Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970
[TBL] [Abstract][Full Text] [Related]
37. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
Middlemas DS; Stewart CF; Kirstein MN; Poquette C; Friedman HS; Houghton PJ; Brent TP
Clin Cancer Res; 2000 Mar; 6(3):998-1007. PubMed ID: 10741727
[TBL] [Abstract][Full Text] [Related]
38. Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.
Barvaux VA; Lorigan P; Ranson M; Gillum AM; McElhinney RS; McMurry TB; Margison GP
Mol Cancer Ther; 2004 Oct; 3(10):1215-20. PubMed ID: 15486188
[TBL] [Abstract][Full Text] [Related]
39. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
[TBL] [Abstract][Full Text] [Related]
40. Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
Zhang J; Stevens MF; Hummersone M; Madhusudan S; Laughton CA; Bradshaw TD
Oncology; 2011; 80(3-4):195-207. PubMed ID: 21720182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]